C0040682||Plasmablastic transformation
C0026764||plasma cell myeloma
C1171362||heterotropic expression
C0108779||CD3
C0003323||CD4
C0007320||case report
C3472614||Plasmablastic lymphoma
C3472614||Plasmablastic lymphoma
C0040682||transformation
C1532559||plasma cell myeloma
C1532559||plasma cell myeloma
C0012634||disease
C0278252||poorer prognosis
C0376636||management
C0026764||plasma cell myeloma
C3472614||Plasmablastic lymphoma
C0079731||B-cell lymphoma
C0226896||oral cavity
C0085393||immunocompromised
C0040682||plasmablastic transformation
C0108779||pan T-cell phenotype
C0108779||CD3
C0003323||CD4
C1512656||immunocompetent
C0011900||diagnosed
C1532559||plasma cell myeloma
C1457868||worsening
C0004604||backache
C0037287||skin nodule
C0556956||left cervical region
C0087111||treatment
C0042679||vincristine
C0010583||cyclophosphamide
C0011777||dexamethasone
C0011777||vincristine, cyclophosphamide, dexamethasone
C1176309||bortezomib
C0005558||biopsy
C0037287||skin nodule
C0332448||infiltrating
C0598798||lymphoid tumor
C0024264||immunoblastic cells
C0026255||mitosis
C0162638||apoptosis
C0021044||Immunohistochemistry
C0021044||Immunohistochemistry
C0086574||lymphoid cells
C0032112||plasma cell
C0005516||markers
C0075742||CD38
C1609943||CD138
C0108754||CD56
C0299544||MUM1
C0108779||Pan-T-cell markers
C0108779||CD3
C0003323||CD4
C1171362||diffusely expressed
C0597032||tumor cells
C0443980||B-cell markers
C0054946||CD20
C0167636||PAX5
C0079068||c-Myc
C0021044||Immunohistochemistry
C0033684||EBER
C0162788||in situ hybridization
C0162788||in situ hybridization
C1513916||negative
C0027651||tumor
C0812425||Mitotic index
C4049944||Ki67
C0011900||diagnosis
C0040682||plasmablastic transformation
C1532559||plasma cell myeloma
C2826610||heterotropic T-cell phenotype
C0040682||plasmablastic transformation
C0026764||plasma cell myeloma
C0011900||diagnose
C0039194||T-cell
C0027651||neoplasms
C0087111||aggressive treatment
C2603343||studies
C1031756||underpinnings
C0024299||lymphoma
C0005532||biology